Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC

Immune checkpoint inhibition leads to response in some patients with head and neck squamous cell carcinoma (HNSCC). Robust biomarkers are lacking to date. We analyzed viral status, gene expression signatures, mutational load and mutational signatures in whole exome and RNA-sequencing data of the HNSCC TCGA dataset (N = 496) and a validation set (DKTK MASTER cohort, N = 10). Public single-cell gene expression data from 17 HPV-negative HNSCC were separately re-analyzed. Among HPV-negative HNSCC, APOBEC3-associated TCW motif mutations but not total single nucleotide variant burden were significantly associated with inflammation. APOBEC3-enriched HPV-negative HNSCC showed higher T-cell inflammation and immune checkpoint expression. Mutations in immune-evasion pathways were enriched in these tumors. APOBEC3B and 3C expression was identified in tumor cells and correlated with tumor inflammation. We identified an APOBEC-enriched subgroup of HPV-negative HNSCC with a distinct immunogenic phenotype, potentially mediating response to immunotherapy.

[1]  S. Fröhling,et al.  Distinct immune evasion in APOBEC‐enriched, HPV‐negative HNSCC , 2020, International journal of cancer.

[2]  F. Jamali,et al.  Single dose pharmacokinetics and bioavailability of glucosamine in the rat. , 2002, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[3]  T. Chan,et al.  APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma. , 2019, Oral oncology.

[4]  M. Stratton,et al.  Characterizing Mutational Signatures in Human Cancer Cell Lines Reveals Episodic APOBEC Mutagenesis , 2019, Cell.

[5]  M. Kloor,et al.  Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden , 2018, Oncoimmunology.

[6]  J. Lunceford,et al.  Pan-tumor genomic biomarkers for PD-1 checkpoint blockade–based immunotherapy , 2018, Science.

[7]  R. Greil,et al.  KEYNOTE-048: Phase III study of first-line pembrolizumab (P) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Jonathan C. Cheng,et al.  Efficacy and safety of pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma: pooled analyses after long-term follow-up in KEYNOTE-012 , 2018, British Journal of Cancer.

[9]  G. Getz,et al.  Genomic correlates of response to immune checkpoint blockade in microsatellite-stable solid tumors , 2018, Nature Genetics.

[10]  M. Jia,et al.  APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer , 2018, Oncogene.

[11]  Paul Hoffman,et al.  Integrating single-cell transcriptomic data across different conditions, technologies, and species , 2018, Nature Biotechnology.

[12]  C. Swanton,et al.  Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  Chi-Ching Lee,et al.  mSignatureDB: a database for deciphering mutational signatures in human cancers , 2017, Nucleic Acids Res..

[14]  Shawn M. Gillespie,et al.  Single-Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Head and Neck Cancer , 2017, Cell.

[15]  Feng Zhang,et al.  Identification of essential genes for cancer immunotherapy , 2017, Nature.

[16]  S. Lantuejoul,et al.  The immune microenvironment of HPV-negative oral squamous cell carcinoma from never-smokers and never-drinkers patients suggests higher clinical benefit of IDO1 and PD1/PD-L1 blockade , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  J. Lunceford,et al.  IFN-&ggr;–related mRNA profile predicts clinical response to PD-1 blockade , 2017, The Journal of clinical investigation.

[18]  J. Meeks,et al.  APOBEC-mediated mutagenesis in urothelial carcinoma is associated with improved survival, mutations in DNA damage response genes, and immune response , 2017, bioRxiv.

[19]  Rob Patro,et al.  Salmon provides fast and bias-aware quantification of transcript expression , 2017, Nature Methods.

[20]  Pornpimol Charoentong,et al.  Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.

[21]  D. Rieke,et al.  Targeted Therapy of Head and Neck Cancer , 2016, Oncology Research and Treatment.

[22]  K. Harrington,et al.  Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. , 2016, The New England journal of medicine.

[23]  J. Lunceford,et al.  Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. , 2016, The Lancet. Oncology.

[24]  G. Freeman,et al.  Correlation of Apobec Mrna Expression with overall Survival and pd-l1 Expression in Urothelial Carcinoma , 2016, Scientific Reports.

[25]  J. Lunceford,et al.  Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). , 2016 .

[26]  A. Sieuwerts,et al.  APOBEC3G Expression Correlates with T-Cell Infiltration and Improved Clinical Outcomes in High-grade Serous Ovarian Carcinoma , 2016, Clinical Cancer Research.

[27]  S. Gabriel,et al.  Genomic correlates of response to CTLA-4 blockade in metastatic melanoma , 2015, Science.

[28]  C. Swanton,et al.  APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity. , 2015, Cancer discovery.

[29]  Nicolai J. Birkbak,et al.  Clonal status of actionable driver events and the timing of mutational processes in cancer evolution , 2015, Science Translational Medicine.

[30]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of head and neck squamous cell carcinomas , 2015, Nature.

[31]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[32]  Kevin P. White,et al.  Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes , 2014, Clinical Cancer Research.

[33]  Steven J. M. Jones,et al.  Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.

[34]  S. Henderson,et al.  APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. , 2014, Cell reports.

[35]  Damian Smedley,et al.  Jannovar: A Java Library for Exome Annotation , 2014, Human mutation.

[36]  A. Furano,et al.  Repair of naturally occurring mismatches can induce mutations in flanking DNA , 2014, eLife.

[37]  The Cancer Genome Atlas Research Network,et al.  Comprehensive molecular characterization of urothelial bladder carcinoma , 2014, Nature.

[38]  T. Samuelsson,et al.  The landscape of viral expression and host gene fusion and adaptation in human cancer , 2013, Nature Communications.

[39]  Steven A. Roberts,et al.  An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers , 2013, Nature Genetics.

[40]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[41]  N. A. Temiz,et al.  Evidence for APOBEC3B mutagenesis in multiple human cancers , 2013, Nature Genetics.

[42]  M. Stratton,et al.  DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis , 2013, eLife.

[43]  Benjamin E. Gross,et al.  Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.

[44]  Justin Guinney,et al.  GSVA: gene set variation analysis for microarray and RNA-Seq data , 2013, BMC Bioinformatics.

[45]  Steven J. M. Jones,et al.  Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.

[46]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[47]  J. Paramio,et al.  Molecular Signature of HPV-Induced Carcinogenesis: pRb, p53 and Gene Expression Profiling , 2009, Current genomics.